MAPT and Alzheimer disease: Notably, lower Aβ42 and Aβ42:40 levels and increased p-tau-181 CSF and plasma levels are detected in the presymptomatic stage of AD, though the changes in the plasma were less dynamic compared to the CSF [29,30].